I'm LongbridgeAI, I can summarize articles.IRLA.US closed the week at $32.03. The five sessions saw an intraweek range of 33.21%. Monday (Oct 12) opened at $29.51 and closed at $32.40 after a sharp gain. Tuesday (Oct 13) fell to a low of $25.13 before closing at $27.87. Wednesday (Oct 14) recovered to $30.00, and Thursday (Oct 15) closed at $33.23. On Friday (Oct 16), the stock hit $34.93 intraday before settling at $32.03. There was no major catalyst this week, and the price largely fluctuated around $31.
The Week
IRLA.US closed the week at $32.03. The five sessions saw an intraweek range of 33.21%. Monday (Oct 12) opened at $29.51 and closed at $32.40 after a sharp gain. Tuesday (Oct 13) fell to a low of $25.13 before closing at $27.87. Wednesday (Oct 14) recovered to $30.00, and Thursday (Oct 15) closed at $33.23. On Friday (Oct 16), the stock hit $34.93 intraday before settling at $32.03. There was no major catalyst this week, and the price largely fluctuated around $31.
Analyst Ratings
Nine firms currently cover IRLA.US: six rate it buy, two overweight, and one hold, with no underweight or sell ratings. The consensus rating is strong buy. The consensus target price is $75, about 134.16% above the latest close. Targets range from $65 to $98, showing wide dispersion. Within the biotech industry, the stock ranks 167th among 509 names.
The Week Ahead
Investors will watch US macro data next week. The NAHB housing market index arrives on Monday (Oct 19), followed by housing starts and building permits on Tuesday (Oct 20), and EIA weekly crude and Cushing inventories on Wednesday (Oct 21). On the company side, IRulya announced on Thursday that it will take part in a fireside chat at the Craig-Hallum Biotech Catalyst Conference, so any follow-up news is worth monitoring.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.